111 related articles for article (PubMed ID: 25092043)
1. Infectious disease. HIV therapy good for HCV infection.
Patman G
Nat Rev Gastroenterol Hepatol; 2014 Sep; 11(9):517. PubMed ID: 25092043
[No Abstract] [Full Text] [Related]
2. Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.
Sherman KE; Guedj J; Shata MT; Blackard JT; Rouster SD; Castro M; Feinberg J; Sterling RK; Goodman Z; Aronow BJ; Perelson AS
Sci Transl Med; 2014 Jul; 6(246):246ra98. PubMed ID: 25101888
[TBL] [Abstract][Full Text] [Related]
3. [The influence of human immunodeficiency virus co-infection with hepatitis C virus and hepatitis B virus on the efficacy of high active anti-retroviral therapy].
Li XF; Kan QC; He Y; Yu ZJ; Li ZQ; Liang HX
Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):951-4. PubMed ID: 21211210
[TBL] [Abstract][Full Text] [Related]
4. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
Zeremski M; Martinez AD; Talal AH
Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
[No Abstract] [Full Text] [Related]
5. HCV/HIV co-infection therapy.
Pietrandoni G
Posit Aware; 2002; 13(2):32, 38. PubMed ID: 12004829
[No Abstract] [Full Text] [Related]
6. Co-Infection Burden of Hepatitis C Virus and Human Immunodeficiency Virus among Injecting Heroin Users at the Kenyan Coast.
Mwatelah RS; Lwembe RM; Osman S; Ogutu BR; Aman R; Kitawi RC; Wangai LN; Oloo FA; Kokwaro GO; Ochieng W
PLoS One; 2015; 10(7):e0132287. PubMed ID: 26208212
[TBL] [Abstract][Full Text] [Related]
7. HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).
Hasson H; Galli L; Gallotta G; Neri V; Blanc P; D'Annunzio M; Morsica G; Sollima S; Merli M; Lazzarin A; Uberti-Foppa C
New Microbiol; 2012 Oct; 35(4):469-74. PubMed ID: 23109014
[TBL] [Abstract][Full Text] [Related]
8. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection.
Torti C; Barnes E; Quiros-Roldan E; Puoti M; Carosi G; Klenerman P
Antivir Ther; 2004 Feb; 9(1):139-42. PubMed ID: 15040546
[No Abstract] [Full Text] [Related]
9. HCV versus HIV drug discovery: Déjà vu all over again?
Watkins WJ; Desai MC
Bioorg Med Chem Lett; 2013 Apr; 23(8):2281-7. PubMed ID: 23489621
[TBL] [Abstract][Full Text] [Related]
10. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.
Macías J; Pineda JA; Lozano F; Corzo JE; Ramos A; León E; García-García JA; Fernández-Rivera J; Mira JA; Gómez-Mateos J
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):675-80. PubMed ID: 14574616
[TBL] [Abstract][Full Text] [Related]
11. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era.
Maida I; Ríos MJ; Pérez-Saleme L; Ramos B; Soriano V; Pegram PS; Mura MS; Sánchez-Margalet V; Saldívar-Cornejo I; Wilkin A; Babudieri S; Núñez M
AIDS Res Hum Retroviruses; 2008 May; 24(5):679-83. PubMed ID: 18462085
[TBL] [Abstract][Full Text] [Related]
12. HIV/Hepatitis C Virus Co-infection among Adults Beginning Antiretroviral Therapy, Malawi.
Demir M; Phiri S; Kaiser R; Chaweza T; Neuhann F; Tweya H; Fätkenheuer G; Steffen HM
Emerg Infect Dis; 2016 Nov; 22(11):2018-2020. PubMed ID: 27767917
[No Abstract] [Full Text] [Related]
13. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
14. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.
Cooper CL; Cameron DW
Clin Infect Dis; 2002 Oct; 35(7):873-9. PubMed ID: 12228825
[TBL] [Abstract][Full Text] [Related]
15. Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells.
Cannizzo ES; Cerrone M; Merlini E; van Wilgenburg B; Swadling L; Ancona G; De Bona A; d'Arminio Monforte A; Klenerman P; Marchetti G
Eur J Immunol; 2019 Jul; 49(7):1127-1129. PubMed ID: 30985000
[No Abstract] [Full Text] [Related]
16. Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
Zhang S; Rust G; Cardarelli K; Felizzola J; Fransua M; Stringer HG
AIDS Care; 2015; 27(7):829-35. PubMed ID: 25814041
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
[TBL] [Abstract][Full Text] [Related]
18. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.
Torre D; Tambini R; Cadario F; Barbarini G; Moroni M; Basilico C
Clin Infect Dis; 2001 Nov; 33(9):1579-85. PubMed ID: 11588701
[TBL] [Abstract][Full Text] [Related]
19. Is active hepatitis C associated with the size of HIV reservoir in successfully treated patients?
Vassallo M; Durant J; Ticchioni M; Demonte A; Fabre R; Pradier C; Cottalorda J
J Clin Virol; 2018 Nov; 108():103-104. PubMed ID: 30290324
[No Abstract] [Full Text] [Related]
20. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
